Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 juil. 2019 09h50 HE | Source: TOLMAR Pharmaceuticals, Inc.

Data on Nadir Testosterone Levels Achieved by ELIGARD® (leuprolide acetate) for injectable suspension published in Reviews in Urology

CHICAGO, July 24, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals, Inc. today announced the publication of a study of nadir testosterone (T) levels achieved in pivotal trials for ELIGARD®...
07 juin 2019 08h55 HE | Source: TOLMAR Pharmaceuticals, Inc.

ELIGARD® (Leuprolide Acetate) for Injectable Suspension Continues Growth Momentum With Securing Favorable Formulary Position as the Lowest WAC Priced, and Only Subcutaneously Administered Leuprolide Acetate for the Palliative Treatment of Advanced Prostate Cancer

CHICAGO, June 07, 2019 (GLOBE NEWSWIRE) -- Tolmar Pharmaceuticals Inc., a fully integrated specialty pharmaceutical company, today announced new formulary placement for ELIGARD® with Rite-Aid’s...